Comments for The Regeneration Station http://regeneration-station.com Stem cells, biomaterials, engineered tissues, and other cell-based technologies. The guts of the Regenerative Medine industry. Wed, 06 May 2009 18:40:22 +0000 http://wordpress.com/ hourly 1 Comment on Pervasis Advances Tissue Engineered Products for Vascular Health by blogfrogger http://regeneration-station.com/2008/01/22/pervasis-furthers-tissue-engineered-products-for-vascular-health/#comment-36 blogfrogger Wed, 06 May 2009 18:40:22 +0000 http://regeneration-station.com/2008/01/22/pervasis-furthers-tissue-engineered-products-for-vascular-health/#comment-36 Very good blog. Very informative. Feel free to add our site to your links in efforts to get even more information out to the renal community. Our site is LifeAlysis www.lifealysis.com Thanks Ross Very good blog. Very informative. Feel free to add our site to your links in efforts to get even more information out to the renal community. Our site is LifeAlysis http://www.lifealysis.com

Thanks
Ross

]]> Comment on Patent Reform Act of 2007 – Impact on Regenerative Medicine by dbellbell http://regeneration-station.com/2007/12/07/patent-reform-act-of-2007-impact-on-regenerative-medicine/#comment-35 dbellbell Mon, 01 Sep 2008 21:38:29 +0000 http://regenerationstation.wordpress.com/2007/12/07/patent-reform-act-of-2007-impact-on-regenerative-medicine/#comment-35 please see http://www.piausa.org/ for a different/opposing view on patent reform please see http://www.piausa.org/ for a different/opposing view on patent reform

]]> Comment on Takin’ a short blog break by attilachordash http://regeneration-station.com/2008/03/01/takin-a-short-blog-break/#comment-34 attilachordash Wed, 12 Mar 2008 21:36:55 +0000 http://regenerationstation.wordpress.com/?p=104#comment-34 I hope your new position will fit eventually to this blog. I know that the industrial biotech blogging space is still nearly empty these days but I strongly suggest continuing your blog and convince other industrial actors to start their own. Positive consequences will come in the long run. I hope your new position will fit eventually to this blog. I know that the industrial biotech blogging space is still nearly empty these days but I strongly suggest continuing your blog and convince other industrial actors to start their own. Positive consequences will come in the long run.

]]> Comment on Celgene Strengthens Adult Stem Cell Patent Estate by Jim H http://regeneration-station.com/2008/01/04/celgene-strengthens-adult-stem-cell-patent-estate/#comment-33 Jim H Thu, 28 Feb 2008 14:15:37 +0000 http://regeneration-station.com/2008/01/04/celgene-strengthens-adult-stem-cell-patent-estate/#comment-33 Jon, My provisional application, does just that: recovers HSC and progenitor ES-like cells from a "non-exsanguinated", intact (whole) afterbirth (not just the placenta, but also cord and amnion). Whether or not the cells derived form this method match the profile that is delineated in these patents remains to be established. Jon,

My provisional application, does just that: recovers HSC and progenitor ES-like cells from a “non-exsanguinated”, intact (whole) afterbirth (not just the placenta, but also cord and amnion).

Whether or not the cells derived form this method match the profile that is delineated in these patents remains to be established.

]]> Comment on Q Therapeutics’ and Invitrogen’s Symbiotic Relationship by jrowley http://regeneration-station.com/2008/02/25/q-therapeutics-and-invitrogens-symbiotic-relationship/#comment-32 jrowley Mon, 25 Feb 2008 23:31:38 +0000 http://regenerationstation.wordpress.com/?p=97#comment-32 To answer your question: I think all life science companies have been watching cell therapy for a long time. They are all trying to figure out how to profit from the field. Some, like Invitrogen, will profit by selling tools (kits and QC assays, GMP-grade culture media and reagents, equipment) to the therapeutic companies, and others, like Celgene, BD or JNJ, will actually be looking to enter the therapeutic arena (much riskier, but more potential reward). I hope that helps - thanks for the comments! To answer your question: I think all life science companies have been watching cell therapy for a long time. They are all trying to figure out how to profit from the field. Some, like Invitrogen, will profit by selling tools (kits and QC assays, GMP-grade culture media and reagents, equipment) to the therapeutic companies, and others, like Celgene, BD or JNJ, will actually be looking to enter the therapeutic arena (much riskier, but more potential reward). I hope that helps – thanks for the comments!

]]>